CRSP - Vertex sickle cell disease drug clears major hurdle for EU approval
2023-12-15 11:56:19 ET
More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc.
- Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics
- Biggest stock movers today: Pfizer, Vertex, Take-Two Interactive, Coherent and more
- Editas gains on Vertex licensing deal for gene editing tech
For further details see:
Vertex sickle cell disease drug clears major hurdle for EU approval